Announced at the Public Report Meeting in Chungcheong Region

Celltrion Pharm will establish a new pre-filled syringe (PFS) production facility in the Chungbuk region, with an investment of 2 trillion won, as a proactive measure to meet growing global demand.


Yoo Young-ho, President of Celltrion Pharm, attended the "Public Report Meeting on the Advanced Industry Development Vision for the Chungcheong Region" held on July 2 in Asan, Chungnam, where he announced this mid-to-long-term investment strategy. Seo Jung-jin, Chairman of Celltrion Group, was seated to the left of President Lee Jae-myung and observed the event.

On the 2nd, at the 'Chungcheong Region Advanced Industry Development Vision Public Report Meeting' held in Asan City, Chungnam Province, President Lee Jae-myung, Seo Jung-jin, Chairman of Celltrion Group, and Lee Jae-yong, Chairman of Samsung Electronics, are watching the event. Screenshot from JTV News YouTube screen.

On the 2nd, at the 'Chungcheong Region Advanced Industry Development Vision Public Report Meeting' held in Asan City, Chungnam Province, President Lee Jae-myung, Seo Jung-jin, Chairman of Celltrion Group, and Lee Jae-yong, Chairman of Samsung Electronics, are watching the event. Screenshot from JTV News YouTube screen.

View original image

According to the detailed implementation schedule disclosed on the same day, the investment will be divided into two phases: the first phase will run from 2028 to 2032, and the second phase will be promoted after 2032, depending on the global demand situation. The total expected investment is 2 trillion won.


President Yoo explained the background for the investment, stating, "Demand for PFS-type pharmaceuticals is rising steeply due to the high convenience and safety of administration for patients. Currently, supply already falls short of demand, and this gap is expected to widen further in the future."


He went on to say, "By adding 50 million syringes to the existing 20 million, we will secure a total production capacity of 70 million syringes. For the first phase, we anticipate an investment of about 1 trillion won, with design and construction starting in 2028, and the goal of full-scale factory operation beginning in 2032." He also emphasized, "We plan to establish a one-stop production system covering everything from formulation, filling, assembly, and packaging, along with in-house material production facilities. This investment plan is not merely an expansion of facilities, but a future investment to grow together with our partners and enhance the national competitiveness of the bio-health industry."


The government also announced support plans to foster the bio industry in the Chungcheong region through large-scale investments. Kim Jungkwan, Minister of Trade, Industry and Energy, cited bio as one of the four core drivers of Chungcheong, calling it an "engine of life," and stated, "Today, a total of 392 trillion won of investment is being ignited in Chungcheong's four engines, including 2 trillion won allocated to bio." Minister Kim added, "We will enhance the global competitiveness of the bio industry through AI-based 'bio foundry (contract manufacturing)."

Youngho Yoo, CEO of Celltrion Pharm, is announcing the mid- to long-term investment strategy at the 'Chungcheong Region Advanced Industry Development Vision National Report Meeting' held on the 2nd in Asan City, Chungcheongnam-do. Screenshot from JTV News YouTube channel

Youngho Yoo, CEO of Celltrion Pharm, is announcing the mid- to long-term investment strategy at the 'Chungcheong Region Advanced Industry Development Vision National Report Meeting' held on the 2nd in Asan City, Chungcheongnam-do. Screenshot from JTV News YouTube channel

View original image

President Lee Jae-myung emphasized the role of entrepreneurs contributing to the advancement of regional high-tech industries, specifically mentioning Chairman Seo. President Lee stated, "Thanks to business leaders like Seo Jung-jin, Chairman of Celltrion, who have tirelessly pioneered new paths in advanced industries, Chungcheong possesses limitless growth potential. With strategic investments from companies and strong commitment from both central and local governments, Chungcheong will emerge as a global hub of innovation leading the AI era."



This announcement marks a significant expansion in both the scale and scope of the previously planned production facility investment. Celltrion had earlier announced an investment of 300 billion won by 2028 in a site of 119,000 square meters within the Naepo Agricultural Life Convergence Industry Cluster in Yesan County. The original plan aimed to self-produce 90% of global DP (Drug Product) volume by combining the Yesan DP plant and expansion of the pre-filled syringe (PFS) facility in Ochang. However, with this announcement, the company committed to a massive investment of 2 trillion won solely in the Ochang PFS facility. Leveraging this expanded facility investment, Celltrion Pharm is expected to respond even more proactively to global biopharmaceutical demand, maximize manufacturing process efficiency, and accelerate efforts to lower production costs.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing